20605-41-8

Usage

Uses

Used in Pharmaceutical Industry:
METHOXYACETIC ACID HYDRAZIDE is used as a key intermediate in the synthesis of Benzylaminopyrazolopyrimidinone derivatives and analogs. These compounds have potential applications as DNA polymerase IIIC inhibitors, which can play a crucial role in the development of novel antiviral and anticancer therapies.
In the synthesis process, METHOXYACETIC ACID HYDRAZIDE can be reacted with appropriate reagents to form the desired Benzylaminopyrazolopyrimidinone derivatives, which can then be further modified or optimized for improved biological activity and selectivity. The development of such inhibitors can contribute to the advancement of targeted therapies for various diseases, including viral infections and cancer.

InChI:InChI=1/C3H8N2O2/c1-7-2-3(6)5-4/h2,4H2,1H3,(H,5,6)

Upstream product

• 625-45-6 2-methoxyacetic acid 
• 3938-96-3 ethyl 2-methoxyacetate 
• 6290-49-9 methyl methoxyacetate 
• 124-41-4 sodium methylate 
• 96-34-4 methyl chloroacetate 

Downstream Products

• 1711-90-6 5-Methyoxymethyl-1,3,4-oxadiazol-2(3H)-on 
• 625-45-6 2-methoxyacetic acid 
• 122432-95-5 Methoxy-acetic acid [1-(2-chloro-phenyl)-eth-(E)-ylidene]-hydrazide 
• 77796-11-3 9-Fluoro-6-(4-fluoro-phenyl)-1-methoxymethyl-5,6-dihydro-4H-2,3,10b-triaza-benzo[e]azulene 
• 133661-70-8 Methoxy-acetic acid [1-(2-chloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 128153-79-7 Methoxy-acetic acid [1-(2,6-dichloro-phenyl)-meth-(E)-ylidene]-hydrazide 
• 220445-35-2 8-chloro-3-methoxymethyl-6-(4-nitrophenyl)-11H-1,2,4-triazolo[4,5-c][2,3]benzodiazepine 
• 452973-97-6 3-methoxymethyl-5-(4-nitro-phenyl)-7,9-dioxa-1,2,3a,4-tetraaza-dicyclopenta[a,g]naphthalene 
• 124806-71-9 3-ethyl-5-methoxymethyl-4-[(2'-carbomethoxybiphenyl-4-yl)methyl]-1,2,4-triazole 
• 124806-70-8 3-Methoxymethyl-5-propyl-4-[(2'-carbomethoxy-biphenyl-4-yl)methyl]-1.2.4-triazole 
• 66437-18-1 2-methoxymethyl-1,3,4-thiadiazole-5-thiol 
• 124806-73-1 3-methoxymethyl-5-propyl-4-[(2'-cyanobiphenyl-4-yl)methyl]-1,2,4-triazole 
• 138624-82-5 2-methoxyacetyl-N-phenylhydrazinecarbothioamide 
• 1188405-72-2 C₂₃H₂₉N₅O₅ 

Relevant academic research and scientific papers

Combinatorial synthesis of 3,5-Dimethylene substituted 1,2,4-Triazoles

Combinatorial cyclizations of imidates and hydrazides with methylene linked R groups, generated from the corresponding nitriles and carboxylic acids, respectively, provided a large library of 3,5-dimethylene substituted 1,2,4- trizoles. 2011 Bentham Science Publishers Ltd.

Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent

A series of aryloxyazetidines, aryloxypyrrolidines and aryloxypiperidines were designed based on structural overlap with previously reported arylpyrazine Oxytocin antagonists. Similarly high levels of Oxytocin antagonism were achievable in these new serie

N-(Acetamido)thiourea based simple neutral hydrogen-bonding receptors for anions

N-(Acetamido)-N′-phenylthioureas (4-6) were found to be efficient anion receptors with higher anion affinity than their N-benzamido-N′- phenylthiourea counterparts (1 and 2). The N′-phenylthiourea moiety in 4-6 was shown to be the chromophore with an absorption maximum at ca. 270 nm. It was found that, in the presence of anions, the absorption at ca. 270 nm of 4-6 (except 5f) in acetonitrile (MeCN) was blue shifted and enhanced while a red-shifted shoulder appeared at ca. 295 nm, together with an isosbestic point at ca. 240 nm. The 1:1 anion binding constants of 4-6, for example at 10 6-107 M-1 order of magnitude for AcO - in MeCN, were found to be higher than those of 1 and 2, although the acidity of the thioureido -NH protons in 4-6 is lower than that in 1 and 2. 1H NMR data indicates that the N-N single bond in 4-6 is twisted but less than that in 1 and 2. A conformation change at the N-N single bond of 4-6 was suggested to occur upon anion binding which leads to a planar hydrogen-bonding network in the anion binding complex in which a charge transfer takes place with the N-acyl moiety being the electron acceptor. Variations in the CD signals of a proline derivative 6 bearing a chiral center in the N-amido moiety provide direct evidence for this conformation change upon its binding with anions in MeCN. The amplified effect of substituent X at the N′-phenyl ring of 5 on the anion binding constant supports the conclusion of anion-binding switched charge transfer in the anion binding complex. 1H NMR and absorption titrations for 5 indicated that the anion-receptor interaction was of a hydrogen-bonding nature until the N′-phenyl substituent X is as electron-withdrawing as m-CF3 (5e). With X being the more electron-withdrawing p-NO2 (5f), deprotonation of the thioureido -NH occurs in the presence of anion. Results reported here confirm that N-amidothioureas derived from both N-aliphatic and N-aromatic amides can in general be a family of efficient hydrogen-bonding receptors, with the aliphatic N-amido derivatives being more efficient. This provides a wider structural diversity for designing thiourea-based functional molecules such as anion receptors and organocatalysts. Preliminary experiments confirm that 6 could catalyse efficiently the reduction of nitrostyrene in CH2Cl2 and MeCN.

Substituted triazole derivatives as oxytocin antagonists

The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy.

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu

PEPTIDIC COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Antihypertensive actions of hydrazidones: Study of acylated dichloroarylhydrazones

A series of acylated dichloroarylhydrazones has been prepared and evaluated on spontaneously hypertensive rats (SHR). The presence of 2-Cl and 6-Cl aromatic substituents in a clonidine like position is not required since derivatives bearing 2- and 4-chloro as well as 3- and 4-chloro substituents exert antihypertensive activities. Activity is also maintained in certain 2,6 disubstituted derivatives where one of the chlorine atoms is replaced by F or NO2.